Terminology of lower urinary tract dysfunction: French adaptation of the terminology of the International Continence Society], Prog Urol. déc, vol.14, issue.6, pp.1103-1114, 2004. ,
Chapter 1: The conditions of neurogenic detrusor overactivity and overactive bladder, Neurourology and Urodynamics, vol.30, issue.S3, pp.2-5, 2014. ,
DOI : 10.1002/nau.22636
Systematic Review of the Epidemiology of Urinary Incontinence and Detrusor Overactivity among Patients with Neurogenic Overactive Bladder, Neuroepidemiology, vol.41, issue.3-4, pp.3-4146, 2013. ,
DOI : 10.1159/000353274
Prognostic value of urodynamic testing in myelodysplastic patients, The Journal of Urology, vol.167, issue.2, pp.1049-53, 1981. ,
DOI : 10.1016/S0022-5347(02)80338-X
Pronostic des vessies neurologiques, Progr??s en Urologie, vol.23, issue.14, pp.1181-1186, 2013. ,
DOI : 10.1016/j.purol.2013.09.023
Does Optimizing Bladder Management Equal Optimizing Quality of Life? Correlation Between Health-related Quality of Life and Urodynamic Parameters in Patients With Spinal Cord Lesions, Urology, vol.74, issue.2, pp.263-269, 2009. ,
DOI : 10.1016/j.urology.2009.02.047
Tibial Nerve Stimulation for Treating Neurogenic Lower Urinary Tract Dysfunction: A Systematic Review, European Urology, vol.68, issue.5 ,
DOI : 10.1016/j.eururo.2015.07.001
Neuromodulation dans la prise en charge des troubles v??sico-sphinct??riens neurologiques, Progr??s en Urologie, vol.17, issue.3, pp.609-624, 2007. ,
DOI : 10.1016/S1166-7087(07)92376-3
Les m??dicaments de la vessie, Progr??s en Urologie, vol.23, issue.15, pp.1271-86, 2013. ,
DOI : 10.1016/j.purol.2013.09.020
Anticholinergic Drugs for Adult Neurogenic Detrusor Overactivity: A Systematic Review and Meta-analysis, European Urology, vol.62, issue.5 ,
DOI : 10.1016/j.eururo.2012.02.036
Incontinence: 5th International Consultation on Incontinence, p.2013 ,
Chapter 4: Guidelines for the diagnosis and treatment of overactive bladder (OAB) and neurogenic detrusor overactivity (NDO), Neurourology and Urodynamics, vol.184, issue.S3, pp.21-26, 2014. ,
DOI : 10.1002/nau.22631
Botulinum toxin injections for adults with overactive bladder syndrome, Cochrane Database Syst Rev, issue.12, p.5493, 2011. ,
Crit??res de d??cision et recommandations de bonne pratique clinique pour la premi??re injection intrad??trusorienne de toxine botulique A dans le traitement de l???hyperactivit?? neurog??ne du d??trusor, Progr??s en Urologie, vol.19, issue.6, pp.372-82, 2009. ,
DOI : 10.1016/j.purol.2009.02.006
Use and mechanism of botulinum toxin in overactive bladder treatment], Ann Urol (Paris). sept, vol.39, pp.3-4105, 2005. ,
Chapitre C-l C - Traitement pharmacologique de l???hyperactivit?? d??trusorienne neurologique : injections intra-d??trusoriennes de toxine botulique A, Progr??s en Urologie, vol.17, issue.3, pp.568-75, 2007. ,
DOI : 10.1016/S1166-7087(07)92370-2
Effects of botulinum A toxin on detrusor-?sphincter dyssynergia in spinal cord injury patients, J Urol. mai, vol.139, issue.5, pp.919-941, 1988. ,
BOTULINUM-A TOXIN FOR TREATING DETRUSOR HYPERREFLEXIA IN SPINAL CORD INJURED PATIENTS: A NEW ALTERNATIVE TO ANTICHOLINERGIC DRUGS? PRELIMINARY RESULTS, The Journal of Urology, vol.164, issue.3, pp.692-699, 2000. ,
DOI : 10.1016/S0022-5347(05)67283-7
Contemporary Management of Lower Urinary Tract Disease With Botulinum Toxin A: A Systematic Review of Botox (OnabotulinumtoxinA) and Dysport (AbobotulinumtoxinA), European Urology, vol.60, issue.4, pp.784-95, 2011. ,
DOI : 10.1016/j.eururo.2011.07.001
Pharmacology of botulinum toxin: differences between type A preparations, European Journal of Neurology, vol.296, issue.Suppl. 8, pp.2-10, 2006. ,
DOI : 10.1111/j.1468-1331.2006.01438.x
Success of Repeat Detrusor Injections of Botulinum A Toxin in Patients with Severe Neurogenic Detrusor Overactivity and Incontinence, European Urology, vol.47, issue.5, pp.653-662, 2005. ,
DOI : 10.1016/j.eururo.2004.11.009
Discontinuation rates and inter-injection interval for repeated intravesical botulinum toxin type???A injections for detrusor overactivity, International Journal of Urology, vol.58, issue.12, pp.175-183, 2014. ,
DOI : 10.1111/iju.12205
Efficacy and Tolerability of Botulinum Toxin Type A in Patients with Neurogenic Detrusor Overactivity and Without Concomitant Anticholinergic Therapy: Comparison of Two Doses, European Urology, vol.58, issue.5, pp.759-66, 2010. ,
DOI : 10.1016/j.eururo.2010.06.035
Success rate and patients' satisfaction following intradetrusor dysport injection in patients with detrusor overactivity: a comparative study of idiopathic and neurogenic types of detrusor overactivity, Urol J. févr, vol.11, issue.1, pp.1289-95, 2014. ,
Intradetrusor injection of botulinum-A toxin in patients with idiopathic and neurogenic detrusor overactivity: Urodynamic outcome and patient satisfaction, Neurourology and Urodynamics, vol.38, issue.4, pp.531-537, 2007. ,
DOI : 10.1002/nau.20403
Neurogenic Detrusor Overactivity Treated with English Botulinum Toxin A: 8-Year Experience of One Single Centre, European Urology, vol.53, issue.5, pp.1013-1022, 2008. ,
DOI : 10.1016/j.eururo.2007.09.034
) make a difference?, BJU International, vol.103, issue.1, pp.94-103, 2013. ,
DOI : 10.1111/bju.12028
Comparison of the Efficacy of OnabotulinumtoxinA and AbobotulinumtoxinA at the 1, Plastic and Reconstructive Surgery, vol.135, issue.1, pp.239-288, 2015. ,
DOI : 10.1097/PRS.0000000000000800
Dysport and Botox at a ratio of 2.5:1 units in cervical dystonia: A double-blind, randomized study, Movement Disorders, vol.12, issue.Suppl 8, pp.206-219, 2015. ,
DOI : 10.1002/mds.26085
Comparison of two different formulations of botulinum toxin A for the treatment of oesophageal achalasia, Alimentary Pharmacology and Therapeutics, vol.48, issue.10, pp.1347-50, 1999. ,
DOI : 10.1002/(SICI)1097-4598(1997)6+<146::AID-MUS10>3.0.CO;2-4
Triple-Blind, Prospective, Internally Controlled Comparative Study Between AbobotulinumtoxinA and OnabotulinumtoxinA for the Treatment of Facial Rhytids, Dermatology and Therapy, vol.12, issue.5 Suppl, pp.179-89, 2013. ,
DOI : 10.1007/s13555-013-0033-y
Long-term treatment of spasticity with botulinum toxin type A: an analysis of 1221 treatments in 137 patients, Neurological Research, vol.4, issue.2, pp.309-322, 2010. ,
DOI : 10.1177/154596830101500108
Definition of botulinum toxin failure in neurogenic detrusor overactivity: Preliminary results of the DETOX survey], Prog Urol. 26 août, 2015. ,
Oui Non Si oui lequel et à quelles doses : Capacité Cystomanométrique Maximale Pression détrusorienne Maximale Volume à la 1ère contraction détrusorienne non Inhibée Modalités de la 1 ère injection -Date de 1 ère injection, Dose totale de Botox®injectée (UI): -Nombre de site d'injection ,
Botox® a-t-elle été augmentée lors de la dernière injection ,
à analyser pour chaque dossier / chaque équipe -la question peut être posée à chaque équipe en dehors de l'analyse dossier/dossier : comment définissez vous l'échec de toxine dans cette indication) -Clinique : persistance de fuites (sans fuite d'effort), infections répétées ,
Dysport® a-t-elle été augmentée lors de la dernière injection ,